Rice Hall James & Associates’s Myriad Genetics MYGN Stock Holding History

Rice Hall James & Associates’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-351,837	Closed	-$9.58M	–	277
2019 Q4	$9.58M	Sell	351,837 -485,811	-58%	-$13.4M	0.32%	107
2019 Q3	$24M	Sell	837,648 -15,731	-2%	-$458K	0.86%	34
2019 Q2	$23.7M	Sell	853,379 -51,534	-6%	-$1.46M	0.79%	35
2019 Q1	$30M	Buy	904,913 +104,360	+13%	+$3.18M	0.97%	30
2018 Q4	$23.3M	Buy	+800,553	New	+$28.8M	0.85%	33
2016 Q3	–	Sell	-526,184	Closed	-$16.1M	–	298
2016 Q2	$16.1M	Buy	+526,184	New	+$18.3M	0.93%	41
2014 Q1	–	Sell	-62,526	Closed	-$1.31M	–	312
2013 Q4	$1.31M	Buy	62,526 +39,592	+173%	+$1M	0.09%	206
2013 Q3	$539K	Sell	22,934 -5,655	-20%	-$161K	0.05%	220
2013 Q2	$768K	Buy	+28,589	New	+$829K	0.08%	197

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rice Hall James & Associates's MYGN Position: Q1 2020 in Review

Rice Hall James & Associates sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 351,837 shares — an estimated $9.58M sold.

Rice Hall James & Associates first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $30M in Q1 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Rice Hall James & Associates reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Rice Hall James & Associates sold 351,837 Myriad Genetics shares in Q1 2020, an estimated $9.58M.
Rice Hall James & Associates first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
Rice Hall James & Associates's Myriad Genetics position peaked at $30M in Q1 2019.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Rice Hall James & Associates's 13F filing for Q1 2020, filed 15 May 2020.